Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02796898 · ClinicalTrials.gov registry record · Phase 1
Study of the Efficacy, Safety, and Pharmacokinetics of SM88 in Patients With Prostate Cancer
A Phase 1 study of Prostate Cancer and Rising Prostate Specific Antigen (PSA), sponsored by Tyme.
- Completed
- Registry status
- Phase 1
- Development phase
- 23
- Enrollment target
- 5
- Study locations
NCT02796898 is a Phase 1 study of Prostate Cancer and Rising Prostate Specific Antigen (PSA) that has completed, run by Tyme. The registered enrollment target is 23 participants, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (96% lower). The trial reports 5 study locations across 3 states.
The verdict
NCT02796898, a Phase 1 study of Prostate Cancer and Rising Prostate Specific Antigen (PSA), has completed, sponsored by Tyme.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 23 participants
- Enrollment target
- 5
- Study locations
Study Summary
The purpose of this study is to evaluate the safety, pharmacokinetics, and efficacy of SM88 in patients with prostate cancer
Conditions Studied
Interventions
- DRUG SM88 (Cohort 1)
- DRUG SM88 (Cohort 2)
Study Locations (5)
New York
- AccuMed Research Associates - Garden City
- Montefiore Medical Center- Montefiore Medical Park - The Bronx
- Eastchester Center for Cancer Care - The Bronx
New Jersey
- AdvanceMed Research - Lawrence
Pennsylvania
- MidLantic Urology - Bala-Cynwyd
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 23 participants |
| Start Date | 2016-06 |
| Est. Completion | 2019-05-30 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02796898
The ClinicalTrials.gov registry entry for NCT02796898 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 23 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (96% lower). The listed sponsor is Tyme, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Prostate Cancer appearing as the primary indexed condition, and to 2 interventions - of which SM88 (Cohort 1) is the first listed.
NCT02796898 reports 5 study locations spanning 3 distinct geographic areas - top geographies include New York, New Jersey, Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT02796898 about?
NCT02796898 is a clinical study titled "Study of the Efficacy, Safety, and Pharmacokinetics of SM88 in Patients With Prostate Cancer". The purpose of this study is to evaluate the safety, pharmacokinetics, and efficacy of SM88 in patients with prostate cancer
What is the current status of trial NCT02796898?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 23 participants. The study started on 2016-06. Estimated completion is 2019-05-30.
What conditions does trial NCT02796898 study?
This clinical trial studies the following conditions: Prostate Cancer, Rising Prostate Specific Antigen (PSA).
What interventions are being tested in trial NCT02796898?
The interventions under investigation include: SM88 (Cohort 1) (DRUG), SM88 (Cohort 2) (DRUG).
Who is sponsoring clinical trial NCT02796898?
This trial is sponsored by Tyme, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02796898 being conducted?
This trial has 5 study locations across New Jersey, New York, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Prostate Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Evaluate Safety, Efficacy, and Pharmacokinetics in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
-
Phase 1 Trial of ZM008 as Single Agent and in Combination With Pembrolizumab in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
-
Study of JANX007 in Subjects With Metastatic Castration-Resistant Prostate Cancer (ENGAGER-PSMA-01)
RECRUITING · Phase 1
-
Study of STM-416p Administered to Patients Undergoing Radical Prostatectomy
RECRUITING · Phase 1
-
A Study to Learn How Safe AZD6621 is, How Well it Works, and How it Moves Throughout the Body Over Time, in Adult Male Participants With Metastatic Prostate Cancer
RECRUITING · Phase 1
-
Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.